All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
CureVac has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The Phase 2b/3 trial called HERALD will assess the safety and efficacy of CVnCoV in adults at a dose of 12 µg.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162b2
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b2
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2020
Details:
In the ongoing Phase 3 clinical study of the vaccine, BNT162b2 met all primary efficacy endpoints, with an efficacy rate of 95% in preventing symptomatic COVID-19 infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
The exact timing for final approval will depend on how many other shots are given the green light over the next few months. CVnCoV is a mRNA-based vaccines would be used for the treatment of COVID 19 infection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
The interim data showed that CVnCoV was generally well tolerated across all tested doses (2-12µg) and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: New Zealand government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 12, 2020
Details:
The New Zealand government signed a deal on Monday to buy 1.5 million COVID-19 vaccines from Pfizer Inc and Germany’s BioNTech, with delivery potentially as early as the first quarter of 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: BioNTech SE
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 07, 2020
Details:
Rentschler Biopharma will be responsible for key aspects of cGMP drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: German Federal Ministry of Education and Research
Deal Size: $438.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 15, 2020
Details:
BioNTech will use the milestone-based BMBF funding to support its contribution to the Company’s mRNA vaccine program BNT162 that is being co-developed with its partners Pfizer Inc. and Fosun Pharma respectively.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2020
Details:
German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 2/3 clinical trial in Germany for their BNT162b2 vaccine candidate. The trial evaluates the safety and efficacy of BNT162b2 in up to 30,000 participants between 18 and 85 years of age.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Fosun Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 27, 2020
Details:
Collaboration aims to supply 10 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, to Hong Kong.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BNT162b1
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b1
Highest Development Status: Phase II/ Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
BNT162b1 was administered in a dose that was well tolerated and generated dose-dependent immunogenicity, as measured by RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
